S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)

Insulet (PODD) Competitors

$178.00
-1.65 (-0.92%)
(As of 09:45 AM ET)

PODD vs. TFX, GMED, NVCR, BAX, RMD, SWAV, PEN, INSP, GKOS, and HAE

Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Teleflex (TFX), Globus Medical (GMED), NovoCure (NVCR), Baxter International (BAX), ResMed (RMD), Shockwave Medical (SWAV), Penumbra (PEN), Inspire Medical Systems (INSP), Glaukos (GKOS), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.

Insulet vs.

Teleflex (NYSE:TFX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Insulet has a net margin of 12.16% compared to Insulet's net margin of 11.98%. Teleflex's return on equity of 32.19% beat Insulet's return on equity.

Company Net Margins Return on Equity Return on Assets
Teleflex11.98% 14.98% 8.87%
Insulet 12.16%32.19%7.93%

95.6% of Teleflex shares are held by institutional investors. 1.4% of Teleflex shares are held by insiders. Comparatively, 0.9% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Insulet had 3 more articles in the media than Teleflex. MarketBeat recorded 6 mentions for Insulet and 3 mentions for Teleflex. Teleflex's average media sentiment score of 1.04 beat Insulet's score of 0.20 indicating that Insulet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teleflex
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Insulet
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.97B3.44$356.33M$7.5328.89
Insulet$1.70B7.41$206.30M$2.9161.74

Insulet received 190 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 65.98% of users gave Insulet an outperform vote while only 59.68% of users gave Teleflex an outperform vote.

CompanyUnderperformOutperform
TeleflexOutperform Votes
518
59.68%
Underperform Votes
350
40.32%
InsuletOutperform Votes
708
65.98%
Underperform Votes
365
34.02%

Teleflex presently has a consensus target price of $265.56, indicating a potential upside of 22.07%. Insulet has a consensus target price of $250.33, indicating a potential upside of 39.35%. Given Teleflex's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Teleflex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teleflex
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60
Insulet
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.81

Teleflex has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Summary

Insulet beats Teleflex on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PODD vs. The Competition

MetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$12.42B$3.83B$4.93B$7.71B
Dividend YieldN/A2.12%2.96%3.91%
P/E Ratio61.7411.58186.6914.46
Price / Sales7.4159.192,339.9794.10
Price / Cash46.7544.2736.0531.39
Price / Book17.134.464.684.40
Net Income$206.30M$4.89M$103.35M$215.04M
7 Day Performance8.88%-0.84%-0.56%-0.61%
1 Month Performance-1.20%-3.35%-0.25%0.14%
1 Year Performance-43.20%14.90%18.42%11.93%

Insulet Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TFX
Teleflex
4.2816 of 5 stars
$217.33
-2.5%
$265.56
+22.2%
-18.4%$10.23B$2.97B28.8614,500Positive News
GMED
Globus Medical
4.8463 of 5 stars
$51.79
-2.5%
$66.33
+28.1%
-10.0%$7.01B$1.02B44.275,000Short Interest ↑
Positive News
NVCR
NovoCure
4.5836 of 5 stars
$14.39
-7.1%
$34.13
+137.1%
-78.4%$1.54B$509.34M-7.381,453Analyst Report
Gap Down
BAX
Baxter International
4.8822 of 5 stars
$42.91
-1.5%
$46.18
+7.6%
-1.8%$21.79B$14.81B8.2260,000Short Interest ↓
RMD
ResMed
4.5244 of 5 stars
$184.37
-2.6%
$199.20
+8.0%
-15.1%$27.12B$4.22B30.4710,140Analyst Revision
SWAV
Shockwave Medical
4.2493 of 5 stars
$319.93
-0.2%
$271.44
-15.2%
+30.7%$11.97B$730.23M82.671,468
PEN
Penumbra
4.9544 of 5 stars
$211.37
-2.8%
$304.45
+44.0%
-22.4%$8.18B$1.06B91.504,200
INSP
Inspire Medical Systems
3.9467 of 5 stars
$205.06
-2.2%
$271.29
+32.3%
-3.2%$6.21B$624.80M-277.111,011Short Interest ↑
GKOS
Glaukos
3.4593 of 5 stars
$89.47
-3.9%
$96.30
+7.6%
+99.9%$4.43B$314.71M-32.18907Analyst Report
Insider Selling
HAE
Haemonetics
4.1063 of 5 stars
$84.17
-0.7%
$104.67
+24.4%
+3.0%$4.27B$1.17B34.223,034Short Interest ↓

Related Companies and Tools

This page (NASDAQ:PODD) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners